This study shows that DLBCL patients with high CDCA2 expression benefitted from the addition of bortezomib to R-CHOP and functional studies documented a direct impact of CDCA2 on the bortezomib response in DLBCL cells. The gene discussed is CDCA2; the disease is diffuse large B-cell lymphoma.